Frontiers17d
Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases
1 Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy 2 Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy Dupilumab is a monoclonal antibody targeting ...
Pharmaceutical Technology18d
Dupilumab by Regeneron Pharmaceuticals for Bullous Pemphigoid: Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...
Pharmaceutical Technology18d
Dupilumab by Regeneron Pharmaceuticals for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...
Frontiers21d
Safety of dupilumab in Chinese pediatric patients aged 6 months and older: a prospective real-world study
Conclusion: Dupilumab has a good safety profile in Chinese children ... Among the ADRs outcomes, 10 cases (15.38%) showed improvement (including 2 cases of allergic conjunctivitis, 4 cases of ...